User menu

Accès à distance ? S'identifier sur le proxy UCLouvain

Search

Displaying 2 results.
    • Journal article
    Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial
    Eng, Cathy Kim, Tae Won Bendell, Johanna Argilés, Guillem Tebbutt, Niall C Di Bartolomeo, Maria Falcone, Alfredo Fakih, Marwan Kozloff, Mark Segal, Neil H Sobrero, Alberto Yan, Yibing Chang, Ilsung Uyei, Anne Roberts, Louise Ciardiello, Fortunato Ahn, JB Asselah, J Badarinath, S Baijal, S Begbie, S Berry, S Canon, JL Carbone, RG Cervantes, A Cha, YJ Chang, K Chaudhry, A Chmielowska, E Cho, SH Chu, D Couture, F Cultrera, J Cunningham, D Van Cutsem, E Cuyle, PJ Davies, J Dowden, S Dvorkin, M Ganju, V Garcia, RV Kerr, R Kim, TY King, K Kortmansky, J Kozloff, M Lam, KO Lee, J Lee, AS Lesperance, B Luppi, G Ma, B Maiello, E Mandanas, R Marshall, J Marx, G Mullamitha, S Nechaeva, M Park, JO Pavlakis, N Ponce, CG Potemski, P Raouf, S Reeves, J Segal, N Siena, S Smolin, A Streb, JO Strickland, A Szutowicz-Zielinska, E Tabernero, JM Tan, B Valera, JS Van den Eynde, Marc[UCL] Vergauwe, P Vickers, M Womack, M Wroblewska, M Young, R (2019) The Lancet Oncology — Vol. 20, no.6, p. 849-861 (2019)
    • Speech
    An international phase II study of cetuximab in combination with oxaliplatin/5-fluorouracil (5-FU/folinic acid (FA) (FOLFOX-4) in the first-line treatment of patients with metastatic colorectal cancer (CRC) expressing Epidermal Growth Factor Receptor (EGFR). Preliminary results.
    Tabernero, JM Humblet, Yves[UCL] Van Cutsem, E. Sastre, J. Cervantes, A. Van Laethem, JL Soulie, P Corretge, S Mueser, M de Gramont, A. (2004) 40th Annual Meeting of the American-Society-of-Clinical-Oncology — New Orleans (La)